TriSalus Life Sciences (NASDAQ:TLSI) versus Hybrid Energy (OTCMKTS:HYBE) Head-To-Head Survey

TriSalus Life Sciences (NASDAQ:TLSI) and Hybrid Energy (OTCMKTS:HYBE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Insider & Institutional Ownership

2.6% of TriSalus Life Sciences shares are held by institutional investors. 27.5% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 6.0% of Hybrid Energy shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares TriSalus Life Sciences and Hybrid Energy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-86.61%	N/A	-116.50%
Hybrid Energy	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for TriSalus Life Sciences and Hybrid Energy, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1	0	4	1	2.83
Hybrid Energy	0	0	0	0	0.00

TriSalus Life Sciences currently has a consensus target price of $10.50, suggesting a potential upside of 139.18%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, research analysts clearly believe TriSalus Life Sciences is more favorable than Hybrid Energy.

Earnings and Valuation

This table compares TriSalus Life Sciences and Hybrid Energy”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$29.43 million	7.44	-$30.05 million	($1.18)	-3.72
Hybrid Energy	N/A	N/A	N/A	N/A	N/A

Hybrid Energy has lower revenue, but higher earnings than TriSalus Life Sciences.

Summary

TriSalus Life Sciences beats Hybrid Energy on 7 of the 9 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Hybrid Energy

Hybrid Energy Holdings, Inc., through its subsidiaries, acquires and operates fuel production and other energy companies. It acquires companies with traditional and proven fuel production, photovoltaic (PV) and solar thermal technologies. Hybrid Energy Holdings, Inc. was formerly known as Comprehensive Healthcare Solutions, Inc. and changed its name to Hybrid Energy Holdings, Inc. in September 2009. Hybrid Energy Holdings, Inc. was incorporated in 1966 and is based in Reno, Nevada. Hybrid Energy Holdings, Inc. is in reorganization.